Wall Street analysts expect Agios Pharmaceuticals (NASDAQ:AGIO) to announce $13.59 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Agios Pharmaceuticals’ earnings, with the highest sales estimate coming in at $17.00 million and the lowest estimate coming in at $10.60 million. Agios Pharmaceuticals posted sales of $10.51 million during the same quarter last year, which suggests a positive year-over-year growth rate of 29.3%. The business is expected to issue its next earnings results before the market opens on Friday, May 4th.
On average, analysts expect that Agios Pharmaceuticals will report full year sales of $111.39 million for the current year, with estimates ranging from $58.30 million to $215.80 million. For the next fiscal year, analysts anticipate that the firm will report sales of $311.22 million per share, with estimates ranging from $85.66 million to $734.10 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The firm had revenue of $9.80 million for the quarter, compared to the consensus estimate of $12.65 million. During the same period last year, the company posted ($1.34) EPS. The business’s revenue was down 56.7% on a year-over-year basis.
A number of research firms recently issued reports on AGIO. Cann reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday. Credit Suisse Group set a $95.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, April 11th. ValuEngine upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BidaskClub upgraded shares of Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 3rd. Finally, SunTrust Banks restated a “buy” rating and issued a $101.00 price target (up from $80.00) on shares of Agios Pharmaceuticals in a research report on Thursday, February 15th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and an average target price of $87.00.
In other Agios Pharmaceuticals news, major shareholder Corp /De/ Celgene acquired 851,154 shares of the company’s stock in a transaction on Tuesday, January 23rd. The shares were purchased at an average cost of $67.00 per share, with a total value of $57,027,318.00. Following the completion of the purchase, the insider now owns 1,374,599 shares of the company’s stock, valued at $92,098,133. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO David P. Schenkein sold 46,408 shares of the stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $80.01, for a total transaction of $3,713,104.08. Following the completion of the sale, the chief executive officer now owns 32,875 shares of the company’s stock, valued at approximately $2,630,328.75. The disclosure for this sale can be found here. Insiders sold 159,880 shares of company stock worth $12,661,668 over the last ninety days. Insiders own 5.43% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Agios Pharmaceuticals by 41.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 762 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in Agios Pharmaceuticals during the fourth quarter valued at approximately $160,000. Bank of Montreal Can lifted its position in Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 1,520 shares during the last quarter. Macquarie Group Ltd. bought a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $245,000. Finally, Xact Kapitalforvaltning AB bought a new stake in Agios Pharmaceuticals during the fourth quarter valued at approximately $259,000. Institutional investors and hedge funds own 82.41% of the company’s stock.
AGIO stock traded up $0.99 during trading on Friday, reaching $87.01. 255,053 shares of the company were exchanged, compared to its average volume of 590,903. The stock has a market cap of $5,006.34, a price-to-earnings ratio of -12.91 and a beta of 1.98. Agios Pharmaceuticals has a twelve month low of $45.11 and a twelve month high of $89.33.
COPYRIGHT VIOLATION NOTICE: This article was published by Macon Daily and is owned by of Macon Daily. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://macondaily.com/2018/04/17/agios-pharmaceuticals-agio-expected-to-post-quarterly-sales-of-13-59-million.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.